Brionic Spółka z Ograniczoną Odpowiedzialnością (KRS 0000412054, NIP 9721238297) is a Polish company, headquartered in Poznań, Wielkopolskie voivodeship. BRIONIC operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since February 23, 2012. BRIONIC's most recently reported net revenue was 13.5 K PLN for 2022.
Historical suspension of activities
Suspension: March 15, 2022 - resumed: June 2, 2025
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Brionic
Identity
- Name
- Brionic Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- February 23, 2012
- Registry status as of
- November 20, 2025
- Latest entry
- June 2, 2025
- Founding act
- 06.02.2012 R., NOTARIUSZ TOMASZ ANTONIAK, KANCELARIA NOTARIALNA W POZNANIU, REP. A NR 845/2012
Articles of association history (2)
- February 6, 2012: 06.02.2012 R., NOTARIUSZ TOMASZ ANTONIAK, KANCELARIA NOTARIALNA W POZNANIU, REP. A NR 845/2012
- September 25, 2017: 25.09.2017 R., REP. A NR 2246/2017, KANCELARIA NOTARIALNA DR ANDRZEJ RATAJ NOTARIUSZ W POZNANIU, UL. SZEWSKA 18, 61-760 POZNAŃ, ZMIANA § 2, § 10 UST. 1, § 15.
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- POZNAŃ, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- POZNAŃ
- ZAWADZKI@G.PL
- Website
- WWW.BRIONIC.PL
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.4079, 16.9335approx.
Risk and payment profile - Brionic
Credibility rating
38.8 / 100
Poor credibility
Insolvency risk
Low
Elevated threat
Closure risk
37
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/14 yrs
Board changes
3
3/14 yrs
PKD changes
1
1/14 yrs
Name changes
1
1/14 yrs
Data from 14 years of registry activity.
Credibility history
Payment reliability score from 2016–2022
Current: E (39/100)
Trend: deteriorating (-6.0 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2016–2022
Current: 272.63 PLN
Safe: 54.53 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Brionic
Founded
February 23, 2012
14 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
POZNAŃ
WIELKOPOLSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
50 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
6 years
2016–2022 · profitable: 0/6
Registry entries
21
latest: June 2, 2025
Risk signals
Revenue
13.5 K PLN
2022
Net profit
-14.9 K PLN
2022
Assets
1.2 K PLN
2022
Equity
1.2 K PLN
2022
EBITDA
N/A
2022
no depreciation data
Valuation
3.1 K PLN
Low confidence
Low confidence
Market comparison Brionic
Comparison with PKD sector 72.19.Z
Market position (2022)
Sector median - total assets
Company - total assets
Public procurement
Trademarks
Reviews
Rate business credibility - Brionic.
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
